Logo image of AQB

AQUABOUNTY TECHNOLOGIES (AQB) Stock Fundamental Analysis

NASDAQ:AQB - Nasdaq - US03842K3095 - Common Stock - Currency: USD

0.85  -0.05 (-5.13%)

Fundamental Rating

2

AQB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. AQB has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AQB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AQB had negative earnings in the past year.
AQB had a negative operating cash flow in the past year.
AQB had negative earnings in each of the past 5 years.
AQB had a negative operating cash flow in each of the past 5 years.
AQB Yearly Net Income VS EBIT VS OCF VS FCFAQB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.40%, AQB is doing worse than 61.50% of the companies in the same industry.
AQB has a Return On Equity (-73.45%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.4%
ROE -73.45%
ROIC N/A
ROA(3y)-11.61%
ROA(5y)-18.33%
ROE(3y)-12.9%
ROE(5y)-21.71%
ROIC(3y)N/A
ROIC(5y)N/A
AQB Yearly ROA, ROE, ROICAQB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

AQB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AQB Yearly Profit, Operating, Gross MarginsAQB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

AQB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AQB has more shares outstanding than it did 1 year ago.
AQB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, AQB has a worse debt to assets ratio.
AQB Yearly Shares OutstandingAQB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AQB Yearly Total Debt VS Total AssetsAQB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -3.64, we must say that AQB is in the distress zone and has some risk of bankruptcy.
AQB has a Altman-Z score (-3.64) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.05 indicates that AQB is not too dependend on debt financing.
AQB has a worse Debt to Equity ratio (0.05) than 62.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.64
ROIC/WACCN/A
WACC6.38%
AQB Yearly LT Debt VS Equity VS FCFAQB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.02 indicates that AQB has no problem at all paying its short term obligations.
The Current ratio of AQB (3.02) is worse than 64.88% of its industry peers.
AQB has a Quick Ratio of 2.98. This indicates that AQB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AQB (2.98) is worse than 63.46% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.98
AQB Yearly Current Assets VS Current LiabilitesAQB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

AQB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.88%.
The Revenue for AQB has decreased by -46.96% in the past year. This is quite bad
Measured over the past years, AQB shows a very strong growth in Revenue. The Revenue has been growing by 98.62% on average per year.
EPS 1Y (TTM)-10.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-46.96%
Revenue growth 3Y166.94%
Revenue growth 5Y98.62%
Sales Q2Q%-93.59%

3.2 Future

AQB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.45% yearly.
The Revenue is expected to grow by 25.81% on average over the next years. This is a very strong growth
EPS Next Y-136.44%
EPS Next 2Y29.94%
EPS Next 3Y0.17%
EPS Next 5Y0.45%
Revenue Next Year-65.64%
Revenue Next 2Y-29.74%
Revenue Next 3Y-42.53%
Revenue Next 5Y25.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AQB Yearly Revenue VS EstimatesAQB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M 8M
AQB Yearly EPS VS EstimatesAQB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AQB. In the last year negative earnings were reported.
Also next year AQB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQB Price Earnings VS Forward Price EarningsAQB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQB Per share dataAQB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.94%
EPS Next 3Y0.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUABOUNTY TECHNOLOGIES

NASDAQ:AQB (5/22/2025, 6:18:13 PM)

0.85

-0.05 (-5.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-04 2025-08-04
Inst Owners12.78%
Inst Owner Change-4.57%
Ins Owners1.86%
Ins Owner Change0%
Market Cap3.29M
Analysts45
Price Target1.02 (20%)
Short Float %4.04%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.81%
Min EPS beat(2)-35.17%
Max EPS beat(2)1.55%
EPS beat(4)1
Avg EPS beat(4)-40.96%
Min EPS beat(4)-88.49%
Max EPS beat(4)1.55%
EPS beat(8)3
Avg EPS beat(8)-19.84%
EPS beat(12)6
Avg EPS beat(12)-11.8%
EPS beat(16)7
Avg EPS beat(16)-15.74%
Revenue beat(2)1
Avg Revenue beat(2)20.22%
Min Revenue beat(2)-37.95%
Max Revenue beat(2)78.4%
Revenue beat(4)1
Avg Revenue beat(4)2.44%
Min Revenue beat(4)-37.95%
Max Revenue beat(4)78.4%
Revenue beat(8)3
Avg Revenue beat(8)-1.66%
Revenue beat(12)4
Avg Revenue beat(12)-5.84%
Revenue beat(16)4
Avg Revenue beat(16)-18.01%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.61
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-7.54
EYN/A
EPS(NY)-2.3
Fwd EYN/A
FCF(TTM)-6.16
FCFYN/A
OCF(TTM)-4.77
OCFYN/A
SpS0.33
BVpS25.86
TBVpS25.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.4%
ROE -73.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-11.61%
ROA(5y)-18.33%
ROE(3y)-12.9%
ROE(5y)-21.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 376.96%
Cap/Sales 425.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 2.98
Altman-Z -3.64
F-Score2
WACC6.38%
ROIC/WACCN/A
Cap/Depr(3y)2283.86%
Cap/Depr(5y)1466.75%
Cap/Sales(3y)1807.69%
Cap/Sales(5y)2010.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y-136.44%
EPS Next 2Y29.94%
EPS Next 3Y0.17%
EPS Next 5Y0.45%
Revenue 1Y (TTM)-46.96%
Revenue growth 3Y166.94%
Revenue growth 5Y98.62%
Sales Q2Q%-93.59%
Revenue Next Year-65.64%
Revenue Next 2Y-29.74%
Revenue Next 3Y-42.53%
Revenue Next 5Y25.81%
EBIT growth 1Y10.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-154.54%
EBIT Next 3Y30.8%
EBIT Next 5Y19.8%
FCF growth 1Y65.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.75%
OCF growth 3YN/A
OCF growth 5YN/A